Login to Your Account



FDA and Company 'Not on Same Page'

Discovery Labs Falls on Third Approvable Letter for Surfaxin

By Catherine Hollingsworth


Monday, May 5, 2008
Discovery Laboratories Inc. received yet another approvable letter from the FDA for Surfaxin use in premature infants with respiratory distress syndrome, causing shares to fall more than 47 percent Friday. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription